New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Alpha-GPC

Pancragen vs Alpha-GPC

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Cognitive Enhancement
Alpha-GPC
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Alpha-GPC is the most bioavailable form of choline, readily crossing the blood-brain barrier to rapidly increase acetylcholine levels. It enhances cognitive performance, supports GH secretion, and is used as an essential complement to many nootropic peptides (especially those that increase acetylcholine demand like Noopept and Dihexa).
Half-Life
Short (minutes); sustained gene-regulatory effects
~4–6 hours
Admin Route
SubQ, Oral
Oral, SubQ
Research
Typical Dose
10 mg per day
300–600 mg
Frequency
Daily for 10–30 days
1–2x daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Rapidly raises brain acetylcholine levels
  • Enhances memory formation and recall
  • Prevents headaches from nootropic peptides (choline donor)
  • Stimulates growth hormone secretion (modest)
  • Improves attention and processing speed
  • Neuroprotective in Alzheimer's and cognitive decline
  • Approved in Europe for Alzheimer's therapy
  • Enhances power output in athletes (pre-workout)
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Headache (paradoxically, from excess acetylcholine at very high doses)
  • Nausea at doses > 1200 mg
  • Dizziness
  • Fatigue at high doses
  • +1 more
Stacks With